“Drug Watch” Website Included In FDA’s Rx Safety Reforms
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will launch a Drug Watch website as part of its drug safety reform initiative
You may also be interested in...
FDA To Name IoM Safety Review Committee Members April 18
The committee will then begin work on a safety study, which is expected to take approximately two years, agency officials say at FDA Science Board meeting. FDA also provides update on other safety initiatives – CDER Acting Deputy Director Throckmorton will chair agency’s Drug Safety Oversight Board.
FDA To Name IoM Safety Review Committee Members April 18
The committee will then begin work on a safety study, which is expected to take approximately two years, agency officials say at FDA Science Board meeting. FDA also provides update on other safety initiatives – CDER Acting Deputy Director Throckmorton will chair agency’s Drug Safety Oversight Board.
Bextra Decision Shows Effort To Improve Drug Safety Transparency, FDA Says
Announcement about the Bextra withdrawal and the addition of "black box" warnings to all prescription NSAIDs was part of FDA's ongoing effort "to improve communication about emerging drug safety concerns," CDER Acting Deputy Director Throckmorton says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: